Get started
Author

Kostas Zervas

Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single‐centre experience in 303 patients
2006 · Kostas Zervas, Evgenia Verrou, et al. · British Journal of Haematology · 296
Bortezomib reduces serum dickkopf‐1 and receptor activator of nuclear factor‐κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma
2006 · Evangelos Terpos, Deborah J. Heath, et al. · British Journal of Haematology · 222
PDF
Natural History of Osteonecrosis of the Jaw in Patients With Multiple Myeloma
2008 · Ashraf Badros, Evangelos Terpos, et al. · Journal of Clinical Oncology · 145
PDF
Treatment with bortezomib‐based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group
2013 · Eirini Katodritou, Evangelos Terpos, et al. · American Journal of Hematology · 73
PDF
Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome?
2009 · E. Katodritou, V. Gastari, et al. · Leukemia Research · 46
The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens
2008 · M. A. Dimopoulos, E. Kastritis, et al. · Haematologica · 44
PDF
Bortezomib is an effective agent for MDS/MPD syndrome with 5q− anomaly and thrombocytosis
2006 · Evangelos Terpos, Evgenia Verrou, et al. · Leukemia Research · 27
On the mechanism of action of recombinant activated factor VII administered to patients with severe thrombocytopenia and life‐threatening haemorrhage: focus on prothrombin activation
2002 · Grigoris T. Gerotziafas, Kostas Zervas, et al. · British Journal of Haematology · 26
PDF
Inhibition of factor VIIa generation and prothrombin activation by treatment with enoxaparin in patients with unstable angina*
2003 · Grigoris T. Gerotziafas, Athanasios Zafiropoulos, et al. · British Journal of Haematology · 18
Multiple myeloma staging based on the combination of beta-2-microglobulin and albumin: The role of albumin in the model
2007 · Dimitra Mihou, Eirini Katodritou, et al. · Hematology · 14
PDF
Evaluation of Hypochromic Erythrocytes in Combination with sT fR-F Index for Predicting Response to r-HuEPO in Anemic Patients with Multiple Myeloma
2006 · Eirini Katodritou, Matthaios Speletas, et al. · Laboratory Hematology · 12
Evaluation of five staging systems in 470 patients with multiple myeloma.
2006 · Dimitra Mihou, Irene Katodritou, et al. · PubMed · 9
Evaluation of Traditional and Novel Predictive Markers of Anemia Response to Recombinant Human Erythropoietin (rh-Epo) in Patients with Multiple Myeloma and Lymphoma: Emerging Role of Functional Iron Deficiency.
2004 · Eirini Katodritou, Matthaios Speletas, et al. · Blood · 7
Bortezomib Reduces Serum Dickkopf-1 and RANKL Concentrations and Normalizes Indices of Bone Remodeling in Patients with Relapsed Multiple Myeloma.
2006 · Evangelos Terpos, Deborah Heath, et al. · Blood · 4
Kinetics of Thrombin Generation in Patients with Multiple Myeloma.
2007 · Anna D. Petropoulou, Grigoris T. Gerotziafas, et al. · Blood · 1
Pulmonary Hypertension after Thalidomide Administration in Multiple Myeloma Patients. Pilot Study.
2007 · Christos Lafaras, Eudokia Mandala, et al. · Blood · 1
Survival analysis of patients with relapsed/refractory multiple myeloma: an interim report from an international electronic observational study of bortezomib
2009 · Michel Delforge, Hadewijch De Samblanx, et al. · Haematologica
Patient Response to Bortezomib in Relapsed/refractory Multiple Myeloma : Interim Results From an Observational Study
2009 · Kostas Zervas, Eirini Katodritou, et al. · Haematologica
A135 Bortezomib International Observational Study in Multiple Myeloma: Baseline Characteristics
2009 · K Zervas, R Dhawan, et al. · Clinical Lymphoma & Myeloma
A425 EGFR Based on Cystatin-C, Creatinine, and Age Is Independently Associated with Survival in Myeloma
2009 · MA Dimopoulos, E Kastritis, et al. · Clinical Lymphoma & Myeloma
P.056 Bisphosphonate osteonecrosis treatment outcome and proposals
2008 · G. Koloutsos, A. Kyrgidis, et al. · Journal of Cranio-Maxillofacial Surgery
Preliminary results from an electronic observational study on bortezomib's effectiveness in advanced multiple myeloma
2008 · Meletios Α. Dimopoulos, Μαρία Ρούσσου, et al. · Haematologica
Pcn3 Effectiveness of Bortezomib in Multiple Myeloma: Preliminary Results From an International Electronic Observational Study
2008 · M Delforge, E Katodritou, et al. · Value in Health
PDF
Dysfunction of Toll-Like Receptor-2, −4, and −6: Is There a Role in the Pathogenesis of Immunodeficiency in Multiple Myeloma?.
2006 · Evangelos Terpos, Meletios A. Dimopoulos, et al. · Blood
Works count: 24
Citation count: 945
H-index: 11
I10-index: 11
Year
Topic
Type